Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Affimed N.V. (AFMD)

Affimed N.V. (AFMD)
0.5400 x 3 0.7500 x 1
Post-market by (Cboe BZX)
0.5701 -0.0619 (-9.79%) 04/04/25 [NASDAQ]
0.5400 x 3 0.7500 x 1
Post-market 0.5800 +0.0099 (+1.74%) 19:18 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.5605
Day High
0.6332
Open 0.6280
Previous Close 0.6320 0.6320
Volume 157,000 157,000
Avg Vol 104,540 104,540
Stochastic %K 3.37% 3.37%
Weighted Alpha -89.20 -89.20
5-Day Change -0.2110 (-27.01%) -0.2110 (-27.01%)
52-Week Range 0.5605 - 8.9500 0.5605 - 8.9500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,179
  • Shares Outstanding, K 16,100
  • Annual Sales, $ 8,960 K
  • Annual Income, $ -114,660 K
  • EBIT $ -76 M
  • EBITDA $ -74 M
  • 60-Month Beta 2.28
  • Price/Sales 9.18
  • Price/Cash Flow N/A
  • Price/Book 0.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.50
  • Most Recent Earnings $-1.03 on 11/14/24
  • Next Earnings Date 03/27/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 200.64% ( -152.20%)
  • Historical Volatility 58.24%
  • IV Percentile 68%
  • IV Rank 22.52%
  • IV High 845.36% on 01/16/25
  • IV Low 13.25% on 10/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 832
  • Open Int (30-Day) 798

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.62
  • Number of Estimates 2
  • High Estimate -0.59
  • Low Estimate -0.65
  • Prior Year -1.38
  • Growth Rate Est. (year over year) +55.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5605 +1.71%
on 04/04/25
Period Open: 0.9770
1.0300 -44.65%
on 03/07/25
-0.4069 (-41.65%)
since 03/04/25
3-Month
0.5605 +1.71%
on 04/04/25
Period Open: 1.3600
1.4100 -59.57%
on 01/06/25
-0.7899 (-58.08%)
since 01/03/25
52-Week
0.5605 +1.71%
on 04/04/25
Period Open: 6.5500
8.9500 -93.63%
on 06/12/24
-5.9799 (-91.30%)
since 04/04/24

Most Recent Stories

More News
Affimed N.V. Reports Promising 40% Complete Remission Rate for AFM28 in Heavily Pretreated R/R AML Patients

AFM28 shows 40% complete remission rate in R/R AML patients with manageable safety profile in Phase 1 trial.Quiver AI SummaryAffimed N.V. announced promising results for its bispecific innate cell engager,...

AFMD : 0.5701 (-9.79%)
Affimed N.V. Reports Encouraging Efficacy of Acimtamig Combined with AlloNK® in R/R Classical Hodgkin Lymphoma at ASH Annual Meeting

Acimtamig with AlloNK® shows 86% response rate in relapsed/refractory classical Hodgkin lymphoma, with manageable safety.Quiver AI SummaryAffimed N.V. announced promising results from a study combining...

AFMD : 0.5701 (-9.79%)
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy

Affimed N.V. AFMD announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its pipeline candidate, acimtamig (AFM13).The regulatory body granted the RMAT designation...

AFMD : 0.5701 (-9.79%)
CSTL : 18.57 (-3.23%)
SPRO : 0.5820 (-6.73%)
ARTV : 2.44 (-3.94%)
Affimed Receives FDA RMAT Designation for Acimtamig and Artiva’s AlloNK® in Relapsed/Refractory Hodgkin Lymphoma Treatment

Affimed's acimtamig and Artiva's AlloNK® receive FDA RMAT designation for treating relapsed/refractory Hodgkin Lymphoma based on promising early data.Quiver AI SummaryAffimed N.V. announced that the U.S....

AFMD : 0.5701 (-9.79%)
Affimed N.V. Completes Enrollment in NSCLC Cohort and Prepares for Data Presentations at ASH 2024

Affimed N.V. reports on clinical trials, financial results, and updates on cash position through Q4 2025.Quiver AI SummaryAffimed N.V. announced the completion of enrollment in the EGFR wild-type non-small...

AFMD : 0.5701 (-9.79%)
Affimed N.V.: Q3 Earnings Snapshot

Affimed N.V.: Q3 Earnings Snapshot

AFMD : 0.5701 (-9.79%)
Affimed N.V.: Q2 Earnings Snapshot

Affimed N.V.: Q2 Earnings Snapshot

AFMD : 0.5701 (-9.79%)
Affimed N.V.: Q1 Earnings Snapshot

Affimed N.V.: Q1 Earnings Snapshot

AFMD : 0.5701 (-9.79%)
Affimed N.V.: Q3 Earnings Snapshot

Affimed N.V.: Q3 Earnings Snapshot

AFMD : 0.5701 (-9.79%)
Affimed N.V.: Q2 Earnings Snapshot

Affimed N.V.: Q2 Earnings Snapshot

AFMD : 0.5701 (-9.79%)

Business Summary

Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V.,...

See More

Key Turning Points

3rd Resistance Point 0.6881
2nd Resistance Point 0.6606
1st Resistance Point 0.6154
Last Price 0.5701
1st Support Level 0.5427
2nd Support Level 0.5152
3rd Support Level 0.4700

See More

52-Week High 8.9500
Fibonacci 61.8% 5.7452
Fibonacci 50% 4.7552
Fibonacci 38.2% 3.7653
Last Price 0.5701
52-Week Low 0.5605

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades